Rigel Pharmaceuticals RIGL fostamatinib — Deferred Revenue

Similar metrics at other companies

FDMTDeferred Revenue — Deferred Revenue

$2.49M—

SDGROncology, Neurology, and Immunology Product — Deferred Revenue

$2.5M—

SDGRDrug discovery — Deferred Revenue

$42.36M-5.6%

VCYTBiopharmaceutical and other revenue — Deferred Revenue

$700K-58.8%

IBT

IBTADeferred revenue — Deferred Revenue

$2.7M-51.8%

SDGRSoftware products and services — Deferred Revenue

$60.76M+0.3%

Questions, answered.

What is Rigel Pharmaceuticals's fostamatinib — deferred revenue?

Rigel Pharmaceuticals (RIGL) reported fostamatinib — deferred revenue of $1.4M in Q1 2026.

How has Rigel Pharmaceuticals's fostamatinib — deferred revenue changed year-over-year?

Rigel Pharmaceuticals's fostamatinib — deferred revenue decreased by 53.3% year-over-year, from $3M to $1.4M.

What does fostamatinib — deferred revenue mean?

Represents the portion of revenue received from customers or partners for the fostamatinib product that has not yet been earned. This liability reflects obligations to provide future goods or services under existing contracts. Monitoring this balance helps investors assess future revenue recognition potential as performance obligations are satisfied.